NCT00923013 · OUTCOME

Minimal Residual Disease (MRD)-Free Survival After Cladribine and up to 2 Courses of Rituximab

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia · Source last updated 2026-08-18

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Testing done 6 months post first dose of treatment, then yearly x2 years and then every 2 years after cladribine indefinitely

What was measured

Compare Cladribine + Rituxan vs cladribine alone in terms of MRD-free survival. MRD free survival time is the time until relapsing from MRD to -free to Complete response. Measured by blood and bone marrow flow cytometry, complete blood count (CBC), and bone marrow immunohistochemistry.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2030-01
denom Units Selected: Participants
description: Compare Cladribine + Rituxan vs cladribine alone in terms of MRD-free survival. MRD free survival time is the time until relapsing from MRD to -free to Complete response. Measured by blood and bone marrow flow cytometry, complete blood count (CBC), and bone marrow immunohistochemistry.
reporting Status: NOT_POSTED
time Frame: Testing done 6 months post first dose of treatment, then yearly x2 years and then every 2 years after cladribine indefinitely
title: Minimal Residual Disease (MRD)-Free Survival After Cladribine and up to 2 Courses of Rituximab
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice